BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 4, 2006
View Archived Issues
Biogen Gains Rights To UCB's CDP323 In $200M Partnership
Adding a fifth product to its portfolio of approved and investigational multiple sclerosis therapies, Biogen Idec Inc. agreed to collaborate on CDP323, an oral alpha-4 integrin inhibitor discovered by UCB. (BioWorld Today)
Read More
MacroGenics Gets $63M From Government, Mostly For WNV
Read More
In Pandemic Flu, Strong Immune Response May Be Good, Or Not
Read More
Xanthus In-Licenses U.S. Rights To Oral Fludarabine
Read More
Other News To Note
Read More
Clinic Roundup
Read More